Loading...
The ongoing search for biomarkers of CDK4/6 inhibitor responsiveness in Breast Cancer
CDK4 inhibitors (CDK4i), such as palbociclib, ribociclib and abemaciclib, are approved in combination with hormonal therapy as a front line treatment for metastatic HR+, Her2− breast cancer. Their targets, CDK4 and CDK6, are cell cycle regulatory proteins governing the G1/S phase transition across m...
Na minha lista:
| Udgivet i: | Mol Cancer Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6951437/ https://ncbi.nlm.nih.gov/pubmed/31909732 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0253 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|